U.S. markets closed
  • S&P 500

    4,266.49
    +24.65 (+0.58%)
     
  • Dow 30

    34,196.82
    +322.58 (+0.95%)
     
  • Nasdaq

    14,369.71
    +97.98 (+0.69%)
     
  • Russell 2000

    2,333.62
    +30.15 (+1.31%)
     
  • Crude Oil

    73.23
    -0.07 (-0.10%)
     
  • Gold

    1,774.90
    -1.80 (-0.10%)
     
  • Silver

    25.99
    -0.06 (-0.25%)
     
  • EUR/USD

    1.1933
    -0.0001 (-0.01%)
     
  • 10-Yr Bond

    1.4870
    0.0000 (0.00%)
     
  • GBP/USD

    1.3921
    0.0000 (-0.00%)
     
  • USD/JPY

    110.8850
    +0.0500 (+0.05%)
     
  • BTC-USD

    34,774.27
    +1,342.41 (+4.02%)
     
  • CMC Crypto 200

    837.58
    +50.96 (+6.48%)
     
  • FTSE 100

    7,109.97
    +35.91 (+0.51%)
     
  • Nikkei 225

    28,875.23
    +0.34 (+0.00%)
     

Constellation Pharmaceuticals to Participate in Investor Conference

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an upcoming virtual investor conference. Jigar Raythatha, CEO, will present at the Goldman Sachs 41st Annual Global Healthcare Conference at 8:00 AM EDT on June 11. A live audio webcast of Mr. Raythatha’s presentation and archives for replay will be available on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events. The audio webcast replay will be available for 30 days following the live presentation.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitors CPI-1205 and CPI0209 for the treatment of metastatic castration-resistant prostate cancer and other cancers. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.

Contacts

Kia Khaleghpour, Ph.D.
Vice President, Investor Relations and Communications
Constellation Pharmaceuticals
+1 617-844-6859
kia.khaleghpour@constellationpharma.com

Ronald Aldridge
Investor Relations
Constellation Pharmaceuticals
+1 617-714-0539
ron.aldridge@constellationpharma.com

Lauren Arnold
Media Relations
MacDougall Biomedical Communications
+1 781-235-3060
larnold@macbiocom.com

Source: Constellation Pharmaceuticals